Firms may expand microdroplet-based applications to include Methyl-Seq and Ultra-Deep Resequencing.
Ambry Genetics and RainDance Technologies are partnering to offer diagnostics and genomics services utilizing the latter’s RDT 1000 sequence enrichment solution . The companies say that Ambry may add Methyl-Seq and Ultra-Deep Resequencing applications during the second half of 2010.
Ambry is a CAP-accredited and CLIA-certified commercial clinical laboratory. The firm specializes in the provision of DNA diagnostic testing for both clinical and research applications. “We are motivated to provide our diagnostic, genomic, and research customers with the best solutions for their projects, and the addition of RainDance’s RDT 1000 adds a sequence-enrichment offering while providing an option for customers that are in need of high-throughput targeted sequencing with a high level of coverage, completeness, and speed,” states Ardy Arianpour, Ambry’s director of business development.
RainDance’s flagship RDT 1000 platform exploits the firm’s RainStorm™ microdroplet-based technology to amplify hundreds to thousands of genomic loci with high specificity and uniformity, the firm claims. While the technology exploits the sensitivity and specificity of PCR, the RDT 1000 is designed to minimize errors and maximize the efficiency of PCR by avoiding the complexities of multiple PCR techniques. The resulting platform also reduces selection bias for decreased complexity and greater integrity of results, according to RainDance.
